A recent survey by Worldwide Clinical Trials showed coordinators' are concerned eCOA interferes with normal patient rapport.
Worldwide Clinical Trials evaluated the experiences of 1,500 clinical study coordinators who use electronic clinical outcome assessment (eCOA) technologies in a global survey and found that 67% of respondents prefer paper-based assessments over eCOA solutions, with many citing concerns that these electronic solutions may interfere with the normal patient rapport that is required during the clinical assessment process. The findings highlight important considerations for the industry, with the need for easier interfaces, simplified set-up processes, and comprehensive training – all vital in improving the usability and prevalence of these technologies.
Worldwide Clinical Trials executives believe that the transition to EDC technologies, across the board, take time but understanding the users' view is important.
Read the full release.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.